Search results
Results From The WOW.Com Content Network
Medical uses for giving cryoprecipitate include: [3] Hypofibrinogenaemia (low fibrinogen levels), or dysfibrinogenaemia as can occur with massive transfusions.; Bleeding from excessive anticoagulation – Fresh frozen plasma contains most of the coagulation factors and is an alternative choice when anticoagulation has to be reversed quickly.
The term cryosupernatant (also called cryo-poor plasma, cryoprecipitate depleted, cryoprecipitate reduced plasma) refers to plasma from which the cryoprecipitate has been removed. It is used to treat thrombocytopenic purpura .
Plasma frozen within 24 hours after phlebotomy, commonly called FP24, [1] PF‑24, or similar names, is a frozen human blood plasma product used in transfusion medicine.It differs from fresh-frozen plasma (FFP) in that it is frozen within 24 hours of blood collection, whereas FFP is frozen within 8 hours.
Fresh frozen plasma (FFP) is a blood product made from the liquid portion of whole blood. [3] It is used to treat conditions in which there are low blood clotting factors (INR > 1.5) or low levels of other blood proteins. [3] [1] It may also be used as the replacement fluid in plasma exchange.
Cryofibrinogenemia refers to a condition classified as a fibrinogen disorder in which a person's blood plasma is allowed to cool substantially (i.e. from its normal temperature of 37 °C to the near-freezing temperature of 4 °C), causing the (reversible) precipitation of a complex containing fibrinogen, fibrin, fibronectin, and, occasionally, small amounts of fibrin split products, albumin ...
Plasmapheresis (from the Greek πλάσμα, plasma, something molded, and ἀφαίρεσις aphairesis, taking away) is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy, a medical procedure performed outside the body. [1]
Prothrombin complex concentrate, cryoprecipitate and fresh frozen plasma are commonly used coagulation factor products. Recombinant activated human factor VII is sometimes used in the treatment of major bleeding. Tranexamic acid and aminocaproic acid inhibit fibrinolysis and lead to a de facto reduced bleeding rate.
Packed red blood cells, fresh frozen plasma, and platelets are generally administered. [131] Typical ratios of fresh frozen plasma, platelets and packed red blood cells are between 1:1:1 and 1:1:2. [132] In some locations, blood has begun to be administered pre-hospital in an effort to reduce preventable deaths from significant blood loss.